CoChat

The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease

Open access
Lonnemann, Niklas, Hosseini, Shirin, Marchetti, Carlo, Skouras, Damaris B., Stefanoni, Davide, D’Alessandro, Angelo, Dinarello, Charles A., Korte, Martin · 2020 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.

Abstract

Significance: IL-1β is an immunomodulatory cytokine that is overexpressed in the brains of patients with Alzheimer’s disease (AD). The NLRP3 inflammasome is an intracellular complex that activates caspase-1, which processes the IL-1β and IL-18 precursors into active molecules. In this study, we used an APP/PS1 mouse model for AD, which confirms significant cognitive losses that are recovered in NLRP3-deficient mice, to evaluate the therapeutic potential of an orally bioavailable and safe NLRP3 inhibitor, OLT1177. OLT1177 ameliorated the phenotype in APP/PS1 mice, as evidenced by rescued spatial learning and memory in the Morris water maze test. Microglia were less activated, cortical plaques reduced, and plasma AD metabolic markers were normalized. OLT1177 is a potential therapeutic option for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2009680117

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Oral administration of OLT1177 in APP/PS1 animals for 3 mo restores cognitive deficits. (A) The treatment of either OLT1177 (3.75 g/kg and 7.5 g/kg; drug per kilogram feed) or control food was started at the age of 6 mo and continued for 3 mo. (B and C) During the treatment period, neither WT nor APP/PS1 mice show differences in weight (n = 16 to 33 animals). (D) WT and APP/PS1 mice indicate a learning behavior during the training phase of the spatial learning test. APP/PS1 mice show higher escape latency during acquisition on day 5 compared to WT mice (day 5 P = 0.037; n = 7 to 12 animals). (E) Moreover, on days 3 and 5 the APP/PS1 mice show increased escape latency compared to APP/PS1 mice treated with 7.5 g/kg OLT1177 (day 3 P = 0.001; day 5 P = 0.007). (F) WT mice and APP/PS1 mice treated with 7.5 g/kg OLT1177 display a significant preference for the TQ, whereas the APP/PS1 mice with control or low dose food did not show any preference (NT vs. TQ: WT P < 0.001; APP/PS1 P > 0.99; APP/PS1 3.75 g/kg P = 0.39; APP/PS1 7.5 g/kg P < 0.001; WT vs. APP/PS1 P = 0.001; WT vs. APP/PS1 3.75 g/kg P = 0.014; WT vs. APP/PS1 7.5 g/kg P = 0.68; APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.0088). (G) WT animals treated with control food, low-dose, or high-dose OLT1177 did not show any differences between the groups. (H) The heat maps of pooled animals manifest the results of the reference test (scale: blue 0 s to red 1.9 s, n = 3 to 4 animals). Data are presented as mean ± SEM. *P < 0.05, ***P < 0.001 compared to WT, ++P < 0.01, +++P < 0.001 compared to APP/PS1 CTRL, ^P < 0.05, ^^^P < 0.001 compared to NT.
Fig. 1. Oral administration of OLT1177 in APP/PS1 animals for 3 mo restores cognitive deficits. (A) The treatment of either OLT1177 (3.75 g/kg and 7.5 g/kg; drug per kilogram feed) or control food was started at the age of 6 mo and continued for 3 mo. (B and C) During the treatment period, neither WT nor APP/PS1 mice show differences in weight (n = 16 to 33 animals). (D) WT and APP/PS1 mice indicate a learning behavior during the training phase of the spatial learning test. APP/PS1 mice show higher escape latency during acquisition on day 5 compared to WT mice (day 5 P = 0.037; n = 7 to 12 animals). (E) Moreover, on days 3 and 5 the APP/PS1 mice show increased escape latency compared to APP/PS1 mice treated with 7.5 g/kg OLT1177 (day 3 P = 0.001; day 5 P = 0.007). (F) WT mice and APP/PS1 mice treated with 7.5 g/kg OLT1177 display a significant preference for the TQ, whereas the APP/PS1 mice with control or low dose food did not show any preference (NT vs. TQ: WT P < 0.001; APP/PS1 P > 0.99; APP/PS1 3.75 g/kg P = 0.39; APP/PS1 7.5 g/kg P < 0.001; WT vs. APP/PS1 P = 0.001; WT vs. APP/PS1 3.75 g/kg P = 0.014; WT vs. APP/PS1 7.5 g/kg P = 0.68; APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.0088). (G) WT animals treated with control food, low-dose, or high-dose OLT1177 did not show any differences between the groups. (H) The heat maps of pooled animals manifest the results of the reference test (scale: blue 0 s to red 1.9 s, n = 3 to 4 animals). Data are presented as mean ± SEM. *P < 0.05, ***P < 0.001 compared to WT, ++P < 0.01, +++P < 0.001 compared to APP/PS1 CTRL, ^P < 0.05, ^^^P < 0.001 compared to NT.CC BY · PubMed Central
Fig. 2. Oral administration of OLT1177 in APP/PS1 animals for 3 mo rescues synaptic plasticity impairment to WT conditions. (A and B) WT and APP/PS1 mice treated either with control food or OLT1177 did not show any differences in the properties of basal synaptic transmission (A, P = 0.72; B, P = 0.843) and (C and D) ratios of pared-pulse facilitation (C, P = 0.22; D, P = 0.19). (E) WT mice treated either with control food or OLT1177 exhibited the same magnitude of LTP in response to strong afferent stimulation (LTP was induced by θ-burst stimulation: TBS, four bursts at 100 Hz repeated 10 times in a 200-ms interval, repeated three times in a 10-s interval; denoted with an arrow) (P = 0.51). (F) Comparison of mean values (average of last 5 min of recordings) LTP magnitude in control mice summarized as bar graphs (P = 0.52). (G) APP/PS1 mice treated with either control food or low dose of OLT1177 showed a significant impairment in LTP induced by TBS compared to control group; however, administration of OLT1177 at high dose could rescue the phenotype in APP/PS1 mice (P < 0.001). (H) The mean LTP magnitude (average of 55 to 60 min after TBS) was significantly lower in APP/PS1 mice treated either with control food or 3.75 mg/kg of OLT1177. Administration of OLT1177 at high dose could rescue the phenotype in APP/PS1 mice (CTRL: 1.661 ± 0.03; APP/PS1: 1.27 ± 0.05; APP/PS1-low dose: 1.23 ± 0.05; and APP/PS1-high dose: 1.52 ± 0.06, P < 0.001). In (E) and (G) a represents the baseline curve and b represents the curve after TBS induction. Data are presented as mean ± SEM. ***P < 0.001 compared to WT, ++P < 0.01 compared to APP/PS1 (n = 6 to 7 animals and n = number of slices in each group = 24 to 36).
Fig. 2. Oral administration of OLT1177 in APP/PS1 animals for 3 mo rescues synaptic plasticity impairment to WT conditions. (A and B) WT and APP/PS1 mice treated either with control food or OLT1177 did not show any differences in the properties of basal synaptic transmission (A, P = 0.72; B, P = 0.843) and (C and D) ratios of pared-pulse facilitation (C, P = 0.22; D, P = 0.19). (E) WT mice treated either with control food or OLT1177 exhibited the same magnitude of LTP in response to strong afferent stimulation (LTP was induced by θ-burst stimulation: TBS, four bursts at 100 Hz repeated 10 times in a 200-ms interval, repeated three times in a 10-s interval; denoted with an arrow) (P = 0.51). (F) Comparison of mean values (average of last 5 min of recordings) LTP magnitude in control mice summarized as bar graphs (P = 0.52). (G) APP/PS1 mice treated with either control food or low dose of OLT1177 showed a significant impairment in LTP induced by TBS compared to control group; however, administration of OLT1177 at high dose could rescue the phenotype in APP/PS1 mice (P < 0.001). (H) The mean LTP magnitude (average of 55 to 60 min after TBS) was significantly lower in APP/PS1 mice treated either with control food or 3.75 mg/kg of OLT1177. Administration of OLT1177 at high dose could rescue the phenotype in APP/PS1 mice (CTRL: 1.661 ± 0.03; APP/PS1: 1.27 ± 0.05; APP/PS1-low dose: 1.23 ± 0.05; and APP/PS1-high dose: 1.52 ± 0.06, P < 0.001). In (E) and (G) a represents the baseline curve and b represents the curve after TBS induction. Data are presented as mean ± SEM. ***P < 0.001 compared to WT, ++P < 0.01 compared to APP/PS1 (n = 6 to 7 animals and n = number of slices in each group = 24 to 36).CC BY · PubMed Central
Fig. 3. Oral administration of OLT1177 in APP/PS1 animals for 3 mo restores dendritic spine loss to WT conditions. (A and B) Dendritic spine density of CA1-apical and -basal was not changed in WT mice following administration of 3.75 g/kg and 7.5 g/kg OLT1177. (C and D) Spine density in both apical and basal dendrites of CA1 hippocampal neuron was significantly diminished in APP/PS1 mice treated either with control food or 3.75 g/kg OLT1177. Administration of 7.5 g/kg OLT1177 could rescue the phenotype in APP/PS1 mice (WT vs. APP/PS1 P = 0.001, WT vs. APP/PS1 3.75 g/kg P = 0.001, WT vs. APP/PS1 7.5 g/kg P = 0.89, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001 in C; WT vs. APP/PS1 P = 0.001, WT vs. APP/PS1 3.75 g/kg P = 0.001, WT vs. APP/PS1 7.5 g/kg P = 0.36, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001 in D). Representative images of dendritic spines of hippocampal CA1 neurons in the tested groups are presented. (Scale bars, 5 µm.) Data are presented as mean ± SEM. ***P < 0.001 compared to WT, +++P < 0.001 compared to APP/PS1 (n = 5 animals and n = 8 dendrites).
Fig. 3. Oral administration of OLT1177 in APP/PS1 animals for 3 mo restores dendritic spine loss to WT conditions. (A and B) Dendritic spine density of CA1-apical and -basal was not changed in WT mice following administration of 3.75 g/kg and 7.5 g/kg OLT1177. (C and D) Spine density in both apical and basal dendrites of CA1 hippocampal neuron was significantly diminished in APP/PS1 mice treated either with control food or 3.75 g/kg OLT1177. Administration of 7.5 g/kg OLT1177 could rescue the phenotype in APP/PS1 mice (WT vs. APP/PS1 P = 0.001, WT vs. APP/PS1 3.75 g/kg P = 0.001, WT vs. APP/PS1 7.5 g/kg P = 0.89, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001 in C; WT vs. APP/PS1 P = 0.001, WT vs. APP/PS1 3.75 g/kg P = 0.001, WT vs. APP/PS1 7.5 g/kg P = 0.36, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001 in D). Representative images of dendritic spines of hippocampal CA1 neurons in the tested groups are presented. (Scale bars, 5 µm.) Data are presented as mean ± SEM. ***P < 0.001 compared to WT, +++P < 0.001 compared to APP/PS1 (n = 5 animals and n = 8 dendrites).CC BY · PubMed Central
Fig. 4. The administration of oral OLT1177 in APP/PS1 animals for 3 mo significantly reduces microglia activation. (A–C) Evaluation of microglial cells by immunostaining of IBA-1 (IBA-1 in red, DAPI in blue) showed no significant differences in activation status of microglial cells between APP/PS1 animals treated with OLT1177 or without (n = 6 to 9, B; n = 12 to 18, C). (Scale bar in A, 100 µm.) (D and E) In addition the percentage of CD68 expressing cells, as an activation marker for microglial cells, was enhanced in CD11b+/CD45low gated cells of APP/PS1 mice treated with control food (WT vs. APP/PS1 P = 0.015, n = 4 to 5 animals). (F–H) Elevation of proinflammatory cytokines IL-1β, IL-6, and TNF-α was detected in brain homogenates of APP/PS1 mice (WT vs. APP/PS1 P = 0.019, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001, F; WT vs. APP/PS1 P = 0.039, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.01, G; APP/PS1 vs. APP/PS1 7.5 g/kg OLT1177 P = 0.011, H; n = 6 to 12 samples). (I) The amount of Aβ plaques was determined using immunostaining for IBA-1 and BAM-10 (clone for Aβ) (IBA-1 in green, DAPI in blue, BAM-10 in red). (Scale bar in I, 500 µm.) (J) Plaque load was lower in the cortex of the APP/PS1 animals fed with 7.5 g/kg OLT1177 compared to APP/PS1 animals (cortex [CX] P = 0.03; hippocampus [HC] P = 0.16, n = 6 in both groups). Data are presented as mean ± SEM. *P < 0.05 compared to WT, +P < 0.05, +++P < 0.001 compared to APP/PS1 CTRL.
Fig. 4. The administration of oral OLT1177 in APP/PS1 animals for 3 mo significantly reduces microglia activation. (A–C) Evaluation of microglial cells by immunostaining of IBA-1 (IBA-1 in red, DAPI in blue) showed no significant differences in activation status of microglial cells between APP/PS1 animals treated with OLT1177 or without (n = 6 to 9, B; n = 12 to 18, C). (Scale bar in A, 100 µm.) (D and E) In addition the percentage of CD68 expressing cells, as an activation marker for microglial cells, was enhanced in CD11b+/CD45low gated cells of APP/PS1 mice treated with control food (WT vs. APP/PS1 P = 0.015, n = 4 to 5 animals). (F–H) Elevation of proinflammatory cytokines IL-1β, IL-6, and TNF-α was detected in brain homogenates of APP/PS1 mice (WT vs. APP/PS1 P = 0.019, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001, F; WT vs. APP/PS1 P = 0.039, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.01, G; APP/PS1 vs. APP/PS1 7.5 g/kg OLT1177 P = 0.011, H; n = 6 to 12 samples). (I) The amount of Aβ plaques was determined using immunostaining for IBA-1 and BAM-10 (clone for Aβ) (IBA-1 in green, DAPI in blue, BAM-10 in red). (Scale bar in I, 500 µm.) (J) Plaque load was lower in the cortex of the APP/PS1 animals fed with 7.5 g/kg OLT1177 compared to APP/PS1 animals (cortex [CX] P = 0.03; hippocampus [HC] P = 0.16, n = 6 in both groups). Data are presented as mean ± SEM. *P < 0.05 compared to WT, +P < 0.05, +++P < 0.001 compared to APP/PS1 CTRL.CC BY · PubMed Central
Fig. 5. Direct effects of OLT1177 on microglia cells in vitro. WT primary microglia cells were cultured and stimulated with 1 µg/mL LPS (E. coli) with or without OLT1177 (5 µM or 10 µM) for 24 h. IL-1β (A), IL-6 (B), and TNF-α (C) were measured in the supernatant. Microglia cells treated with 5 µM OLT1177 showed a significantly reduced release of all three cytokines compared to cells treated with LPS alone (IL-1β LPS vs. LPS 5 µM OLT P = 0.02; LPS vs. LPS 10 µM OLT P = 0.01, A; IL-6 LPS vs. LPS 5 µM OLT P = 0.001, LPS vs. LPS 10 µM OLT P = 0.57, B; TNF-α LPS vs. LPS 5 µM OLT P = 0.006; LPS vs. LPS 10 µM OLT P = 0.054, C). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to WT microglia stimulated with LPS.
Fig. 5. Direct effects of OLT1177 on microglia cells in vitro. WT primary microglia cells were cultured and stimulated with 1 µg/mL LPS (E. coli) with or without OLT1177 (5 µM or 10 µM) for 24 h. IL-1β (A), IL-6 (B), and TNF-α (C) were measured in the supernatant. Microglia cells treated with 5 µM OLT1177 showed a significantly reduced release of all three cytokines compared to cells treated with LPS alone (IL-1β LPS vs. LPS 5 µM OLT P = 0.02; LPS vs. LPS 10 µM OLT P = 0.01, A; IL-6 LPS vs. LPS 5 µM OLT P = 0.001, LPS vs. LPS 10 µM OLT P = 0.57, B; TNF-α LPS vs. LPS 5 µM OLT P = 0.006; LPS vs. LPS 10 µM OLT P = 0.054, C). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to WT microglia stimulated with LPS.CC BY · PubMed Central
Fig. 6. APP/PS1 mice show increases in plasma metabolic markers of AD that are normalized by OLT1177 treatment. Metabolomics analyses were performed on plasma from WT and APP/PS1 mice, either untreated or fed 3.75 or 7.5 g/kg OLT1177. (A) Multivariate analyses of metabolomics data, including partial least-square discriminant analysis and (B) hierarchical clustering analysis of the top 50 significant metabolites by ANOVA revealed a significant effect of APP/PS1 on plasma metabolism compared to controls. (C–E) Significant effects of APP/PS1 and OLT1177 treatment were noted with respect to carboxylic acids (C), glutaminolysis (D), deaminated purines (e.g., allantoate), glutathione turnover metabolites (5-oxoproline), proteolysis (including the urea cycle intermediate ornithine), and tryptophan catabolism (kynurenine) (E). (F) Polyunsaturated fatty acids were decreased in the bloodstream of APP/PS1 mice and normalized by 7.5 g/kg OLT1177. (G) An overview of the overall impact of APP/PS1 and OLT1177 (higher dose) on mouse plasma metabolism is provided in G. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to WT, +P < 0.05, ++P < 0.01, +++P < 0.001 compared to APP/PS1 CTRL (one-way ANOVA and with multiple column comparison).
Fig. 6. APP/PS1 mice show increases in plasma metabolic markers of AD that are normalized by OLT1177 treatment. Metabolomics analyses were performed on plasma from WT and APP/PS1 mice, either untreated or fed 3.75 or 7.5 g/kg OLT1177. (A) Multivariate analyses of metabolomics data, including partial least-square discriminant analysis and (B) hierarchical clustering analysis of the top 50 significant metabolites by ANOVA revealed a significant effect of APP/PS1 on plasma metabolism compared to controls. (C–E) Significant effects of APP/PS1 and OLT1177 treatment were noted with respect to carboxylic acids (C), glutaminolysis (D), deaminated purines (e.g., allantoate), glutathione turnover metabolites (5-oxoproline), proteolysis (including the urea cycle intermediate ornithine), and tryptophan catabolism (kynurenine) (E). (F) Polyunsaturated fatty acids were decreased in the bloodstream of APP/PS1 mice and normalized by 7.5 g/kg OLT1177. (G) An overview of the overall impact of APP/PS1 and OLT1177 (higher dose) on mouse plasma metabolism is provided in G. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to WT, +P < 0.05, ++P < 0.01, +++P < 0.001 compared to APP/PS1 CTRL (one-way ANOVA and with multiple column comparison).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 300

Metadata

Authors
Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M.
Affiliations
  • Technische Universität Braunschweig (DE)
  • Helmholtz Centre for Infection Research (DE)
  • University of Colorado Anschutz (US)
  • Olatec (United States) (US)
  • University of Colorado Denver (US)
  • Radboud University Nijmegen (NL)
  • Department of Cellular Neurobiology, Zoological Institute, Technische Universität Braunschweig, 38106 Braunschweig, Germany;
Corresponding author
Dinarello, Charles A.
Venue
Proceedings of the National Academy of Sciences
Published
2020-11-30
Volume
117
Issue
50
Pages
32145-32154
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3108308610
Cited by
298
References
74
Citations by year
2026: 51 · 2025: 53 · 2024: 50 · 2023: 56 · 2022: 55 · 2021: 33
FWCI
21.81
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-nd)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (AI15614)
  • Deutsche Forschungsgemeinschaft (SFB854)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
NLRP3 inflammasome, Alzheimer's disease, cognitive impairment, IL-1β, caspase-1, APP/PS1 mice, microglial activation, amyloid plaques, spatial learning and memory, anti-inflammatory therapy
MeSH terms
Behavior Observation Techniques, NLR Family, Pyrin Domain-Containing 3 Protein, Administration, Oral, Alzheimer Disease, Animals, Behavior, Animal, Cerebral Cortex, Disease Models, Animal, Humans, Male, Mice, Transgenic, Neuronal Plasticity, Nitriles, Sulfones, Amyloid beta-Protein Precursor, Microglia, Mice, Presenilin-1, Inflammasomes, Cognitive Dysfunction, Spatial Memory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. https://app.cochat.ai/papers/10.1073/pnas.2009680117
The paper
Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M. (2020). The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2009680117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.